menu

Delivering Change: Mechanisms to Address Racial Healthcare Disparities in Multiple Myeloma

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Delivering Change: Mechanisms to Address Racial Healthcare Disparities in Multiple Myeloma

0.25 credits
15 minutes
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.25 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    Multiple myeloma (MM) is the most common hematologic malignancy among African Americans, so it’s important that healthcare providers are aware of the disparities in the treatment provided to Black patients and White patients with MM. Listen in as Drs. Joseph Mikhael, Brandon Blue, and Monique Hartley-Brown discuss strategies to manage racial disparities and begin closing these gaps to ensure all patients receive the care they need.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Joseph Mikhael, MD
    Professor, Division of Applied Cancer Research and Drug Discovery
    Translational Genomics Research Institute
    City of Hope Comprehensive Cancer Center
    Phoenix, AZ

    Consulting fees: Amgen, Bristol Myers Squibb, GlaxoSmithKline, Karyopharm, Janssen Pharmaceuticals, Inc., Sanofi-Aventis US Inc., Takeda Pharmaceuticals

    Faculty:
    Brandon Blue, MD
    Hematologist
    Moffitt Cancer Center
    Magnolia Campus
    Tampa, FL

    Consulting Fees: Janssen, Oncopeptides, Pfizer, Sanofi

    Monique Hartley-Brown, MD, MMSc
    Member, Faculty of Medicine, Harvard Medical School
    Department of Medical Oncology, Dana-Farber Cancer Institute
    Boston, MA

    Research: Amgen, C4 Therapeutics, GlaxoSmithKline, Janssen
    Ownership Interest: Amgen
    Consulting Fees: Amgen, GlaxoSmithKline, Janssen

    Reviewers/Content Planners/Authors:

    • Stephen Chavez has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Tim Person has nothing to disclose.
    • Colleen Resnick has nothing to disclose.
    • Mara Siegel has nothing to disclose.
    • Rosanne Strauss has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Recognize the prevalence of monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and multiple myeloma (MM) among African Americans
    • Evaluate appropriate tests to more rapidly diagnose MGUS, SMM, and MM in high-risk populations
    • Discuss disparities in treatment between Black and White patients with MM
    • Address barriers to clinical trial enrollment for African Americans with MM
  • Target Audience

    This activity is designed to meet the educational needs of hematologist oncologists and oncologists.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

    Distributed With:

  • Commercial Support

    This activity is supported by an independent educational grant from Janssen Scientific Affairs, LLC .

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Multiple myeloma (MM) is the most common hematologic malignancy among African Americans, so it’s important that healthcare providers are aware of the disparities in the treatment provided to Black patients and White patients with MM. Listen in as Drs. Joseph Mikhael, Brandon Blue, and Monique Hartley-Brown discuss strategies to manage racial disparities and begin closing these gaps to ensure all patients receive the care they need.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Joseph Mikhael, MD
    Professor, Division of Applied Cancer Research and Drug Discovery
    Translational Genomics Research Institute
    City of Hope Comprehensive Cancer Center
    Phoenix, AZ

    Consulting fees: Amgen, Bristol Myers Squibb, GlaxoSmithKline, Karyopharm, Janssen Pharmaceuticals, Inc., Sanofi-Aventis US Inc., Takeda Pharmaceuticals

    Faculty:
    Brandon Blue, MD
    Hematologist
    Moffitt Cancer Center
    Magnolia Campus
    Tampa, FL

    Consulting Fees: Janssen, Oncopeptides, Pfizer, Sanofi

    Monique Hartley-Brown, MD, MMSc
    Member, Faculty of Medicine, Harvard Medical School
    Department of Medical Oncology, Dana-Farber Cancer Institute
    Boston, MA

    Research: Amgen, C4 Therapeutics, GlaxoSmithKline, Janssen
    Ownership Interest: Amgen
    Consulting Fees: Amgen, GlaxoSmithKline, Janssen

    Reviewers/Content Planners/Authors:

    • Stephen Chavez has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Tim Person has nothing to disclose.
    • Colleen Resnick has nothing to disclose.
    • Mara Siegel has nothing to disclose.
    • Rosanne Strauss has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Recognize the prevalence of monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and multiple myeloma (MM) among African Americans
    • Evaluate appropriate tests to more rapidly diagnose MGUS, SMM, and MM in high-risk populations
    • Discuss disparities in treatment between Black and White patients with MM
    • Address barriers to clinical trial enrollment for African Americans with MM
  • Target Audience

    This activity is designed to meet the educational needs of hematologist oncologists and oncologists.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

    Distributed With:

  • Commercial Support

    This activity is supported by an independent educational grant from Janssen Scientific Affairs, LLC .

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule21 Apr 2024